Kosan restructures

KOSN restructured and reduced its headcount by 39 employees (33%) to 80 to focus on its clinical programs. The company has two compounds in Phase II testing for breast cancer: KOS-862, an epothilone polyketide, and KOS-953, an ansamycin antibiotic that binds to and inhibits hsp90. KOS-862 is partnered with Roche (SWX:ROCZ). ...